Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.

In this work, hollow mesoporous silica nanoparticles (HMSNs) with three pore sizes were manufactured to control the drug release rate, and the biological roles of these HMSNs were evaluated in multidrug-resistant (MDR) cancer cells. As novel pore-size-controllable inorganic materials, HMSNs showed negligible cytotoxicity and efficient cellular uptake toward drug-sensitive MCF-7 and drug-resistant MCF-7/ADR cells. Doxorubicin (DOX)-loaded HMSNs (DMSNs) not only demonstrated effective drug loading and a pH-responsive drug release character but also exhibited pore-size-dependent and sustained drug release performance in both in vitro and intracellular drug release experiments. In addition, DMSNs exhibited pore-size-dependent anticancer activity against MCF-7/ADR cells. DMSNs with larger pore size could mediate more cellular uptake of DOX and faster intracellular drug release, which led to more intracellular drug accumulation and stronger MDR-reversal effects. The MDR-overcoming mechanism could be due to the efficient cellular uptake, P-gp inhibition, and ATP depletion. These results demonstrate that HMSNs could be a very promising drug delivery system for pore-size-controllable drug release and cancer MDR reversion.

[1]  C. Chu,et al.  Reversible pore-structure evolution in hollow silica nanocapsules: large pores for siRNA delivery and nanoparticle collecting. , 2011, Small.

[2]  Dong Chen,et al.  Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. , 2011, ACS nano.

[3]  Z. Su,et al.  Uniform hollow mesoporous silica nanocages for drug delivery in vitro and in vivo for liver cancer therapy , 2011 .

[4]  Rui L. Reis,et al.  Controlled Delivery Systems: From Pharmaceuticals to Cells and Genes , 2011, Pharmaceutical Research.

[5]  S. Sahoo,et al.  PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.

[6]  Xinglu Huang,et al.  Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. , 2011, Biomaterials.

[7]  K. Singh,et al.  Liposome-mesoporous silica nanoparticles fused cores: a safer mode of drug carrier. , 2011, Journal of biomedical nanotechnology.

[8]  Yaping Li,et al.  Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. , 2011, Biomaterials.

[9]  Feng Chen,et al.  Multifunctional Mesoporous Nanoellipsoids for Biological Bimodal Imaging and Magnetically Targeted Delivery of Anticancer Drugs , 2011 .

[10]  Edouard C. Nice,et al.  Bypassing Multidrug Resistance in Cancer Cells with Biodegradable Polymer Capsules , 2010, Advanced materials.

[11]  Dong Chen,et al.  In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. , 2010, ACS nano.

[12]  Yu Chen,et al.  Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. , 2010, ACS nano.

[13]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[14]  C. Dubernet,et al.  Folic acid-targeted mesoporous silica nanoparticles for two-photon fluorescence. , 2010, Journal of biomedical nanotechnology.

[15]  Liang Zhao,et al.  P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. , 2010, ACS nano.

[16]  Juan L. Vivero-Escoto,et al.  Tuning the cellular uptake and cytotoxicity properties of oligonucleotide intercalator-functionalized mesoporous silica nanoparticles with human cervical cancer cells HeLa. , 2010, Biomaterials.

[17]  Feng Chen,et al.  Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. , 2010, ACS nano.

[18]  Paul C. Wang,et al.  Circumventing tumor resistance to chemotherapy by nanotechnology. , 2010, Methods in molecular biology.

[19]  Yong-soo Lee,et al.  Doxorubicin Exerts Cytotoxic Effects through Cell Cycle Arrest and Fas-Mediated Cell Death , 2009, Pharmacology.

[20]  Yuquan Wei,et al.  Poly(epsilon-caprolactone)/poly(ethylene glycol)/poly(epsilon-caprolactone) nanoparticles: preparation, characterization, and application in doxorubicin delivery. , 2009, The journal of physical chemistry. B.

[21]  M. S. Muthu,et al.  Stimulus-responsive targeted nanomicelles for effective cancer therapy. , 2009, Nanomedicine.

[22]  F. Gao,et al.  Magnetic nanoparticle of Fe3O4 and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells , 2009, International journal of nanomedicine.

[23]  J. Samitier,et al.  Stem cell differentiation by functionalized micro- and nanostructured surfaces. , 2009, Nanomedicine.

[24]  De-gang Fu,et al.  Effect of surface chemistry modification of functional gold nanoparticles on the drug accumulation of cancer cells. , 2008, Journal of biomedical materials research. Part A.

[25]  P. Couvreur,et al.  A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Victor S-Y Lin,et al.  Mesoporous silica nanoparticles for intracellular delivery of membrane-impermeable proteins. , 2007, Journal of the American Chemical Society.

[27]  Cato T Laurencin,et al.  Polymeric nanofibers as novel carriers for the delivery of therapeutic molecules. , 2006, Journal of nanoscience and nanotechnology.

[28]  S. Qiu,et al.  A controlled release of ibuprofen by systematically tailoring the morphology of mesoporous silica materials , 2006 .

[29]  Shilun Qiu,et al.  Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica , 2006 .

[30]  E. Ho,et al.  Regulation of multidrug resistance by pro-inflammatory cytokines. , 2006, Current cancer drug targets.

[31]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[32]  B. Aggarwal,et al.  Role of chemopreventive agents in cancer therapy. , 2004, Cancer letters.

[33]  D. Lake,et al.  High-dose chemotherapy in breast cancer. , 2004, Drugs.

[34]  Deenu Kanjickal,et al.  Modeling of drug release from polymeric delivery systems--a review. , 2004, Critical reviews in therapeutic drug carrier systems.

[35]  H. Coley,et al.  Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[36]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[37]  이병준,et al.  Poly(ε-caprolactone)-Poly(ethylene glycol)-Poly(ε-caprolactone) 블록 공중합체의 물리적 성질 및 열적 성질에 관한 연구 , 2001 .

[38]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[39]  E Harper,et al.  Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  M. Boroujerdi,et al.  Investigation of the relative affinity of doxorubicin for neutral and negatively charged particulate carriers , 1993 .